The current PE ratio of MRVI cannot be calculated, as the latest EPS of -$0.9 is negative. The last PE ratio of Maravai Lifesciences Holdings, recorded in September 2023, was 55.56.
The PE ratio of Maravai Lifesciences Holdings has averaged 15.98 over the last four years. Looking back at the last four years, MRVI's PE ratio peaked in the Sep 2023 quarter at 55.56, when the price was $10 and the EPS was $0.18. The lowest point was in the Dec 2020 quarter, when it reached 3.78 with a price of $28.05 and an EPS of $7.43.
Maximum annual increase: 597.09% in 2021
Maximum annual decrease: -67.48% in 2022
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2022 | 8.57 | -67.48% |
| 2021 | 26.35 | 597.09% |
| 2020 | 3.78 | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| Stock name | PE ratio | Market cap |
|---|---|---|
| NVCR NovoCure Ltd | N/A | $1.35B |
| NVAX Novavax Inc | N/A | $611.6M |
| MRVI Maravai Lifesciences Holdings Inc | N/A | $1.99B |
The current price to earnings ratio of MRVI cannot be determined, as its EPS of -$0.9 is negative.
The average PE ratio for MRVI stock over the past 3 years is 18.33.
Over the last four years, the quarterly PE ratio reached its highest level at 55.56 in the Sep 2023 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.